Literature DB >> 10506602

Telomerase activity and prognosis in primary breast cancers.

L A Carey1, N W Kim, S Goodman, J Marks, G Henderson, C B Umbricht, J S Dome, W Dooley, S R Amshey, S Sukumar.   

Abstract

PURPOSE: Recent studies associate telomerase activity with prognostic factors and survival. We compared quantitative telomerase activity in primary tumors with traditional prognostic factors and outcome in a group of invasive but nonmetastatic breast cancers. PATIENTS AND METHODS: Telomerase activity was measured in 203 invasive breast cancers by the quantitative telomeric repeat amplification protocol method. Telomerase expression was compared with 28S rRNA level, tumor content, and clinical variables, including outcome. For clinical correlations, telomerase activity was standardized by two methods: (1) a correction for cellularity using 28S rRNA levels, and (2) a correction for the histologically determined invasive proportion of the specimen.
RESULTS: Telomerase activity was found in 82% of breast cancers with measurable 28S rRNA levels. Telomerase activity was associated with the proliferative index (P <.01) of the tumor but not with any other prognostic variable. Neither uncorrected nor corrected telomerase activity was associated with relapse-free or overall survival in this study.
CONCLUSION: Telomerase activity level was associated with the proliferative index of invasive breast cancers, but its measurement in samples from this group of nonmetastatic breast cancer patients did not predict survival.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10506602     DOI: 10.1200/JCO.1999.17.10.3075

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  12 in total

Review 1.  Gene expression in breast cancer.

Authors:  Virginia G Kaklamani; William J Gradishar
Journal:  Curr Treat Options Oncol       Date:  2006-03

Review 2.  Telomere shortening occurs early during breast tumorigenesis: a cause of chromosome destabilization underlying malignant transformation?

Authors:  Alan K Meeker; Pedram Argani
Journal:  J Mammary Gland Biol Neoplasia       Date:  2004-07       Impact factor: 2.673

3.  A study on telomerase activity and prognosis in breast cancer.

Authors:  M Kimura; T Koida; Y Yanagita
Journal:  Med Oncol       Date:  2003       Impact factor: 3.064

4.  Telomerase activity in breast cancer patients: association with poor prognosis and more aggressive phenotype.

Authors:  Ana Kulić; Natalija Dedić Plavetić; Stjepan Gamulin; Jasminka Jakić-Razumović; Damir Vrbanec; Maja Sirotković-Skerlev
Journal:  Med Oncol       Date:  2016-01-30       Impact factor: 3.064

5.  Telomerase detection in the diagnosis and prognosis of cancer.

Authors:  Eiso Hiyama; Keiko Hiyama
Journal:  Cytotechnology       Date:  2004-06       Impact factor: 2.058

6.  Troglitazone suppresses telomerase activity independently of PPARgamma in estrogen-receptor negative breast cancer cells.

Authors:  Fariborz Rashid-Kolvear; Michael A S Taboski; Johnny Nguyen; Dong-Yu Wang; Lea A Harrington; Susan J Done
Journal:  BMC Cancer       Date:  2010-07-22       Impact factor: 4.430

7.  Antiproliferative effects of cucurbitacin B in breast cancer cells: down-regulation of the c-Myc/hTERT/telomerase pathway and obstruction of the cell cycle.

Authors:  Suwit Duangmano; Sumana Dakeng; Weena Jiratchariyakul; Apichart Suksamrarn; Duncan R Smith; Pimpicha Patmasiriwat
Journal:  Int J Mol Sci       Date:  2010-12-22       Impact factor: 5.923

Review 8.  Telomere and Telomerase Therapeutics in Cancer.

Authors:  Yucheng Xu; Amir Goldkorn
Journal:  Genes (Basel)       Date:  2016-05-26       Impact factor: 4.096

Review 9.  An introduction to telomeres and telomerase.

Authors:  Michael C Bibby
Journal:  Mol Biotechnol       Date:  2003-07       Impact factor: 2.860

10.  Telomerase reverse transcriptase methylation predicts lymph node metastasis and prognosis in patients with gastric cancer.

Authors:  Yongxin Wu; Guichao Li; Dong He; Fengping Yang; Guang He; Lin He; Hui Zhang; Yun Deng; Ming Fan; Lijun Shen; Daizhan Zhou; Zhen Zhang
Journal:  Onco Targets Ther       Date:  2016-01-11       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.